Bioretec as an investment

Bioretec's goal is to improve the quality of life of people worldwide through innovation that can cure bone fractures more sustainably and with fewer surgeries. Bioretec's products are an excellent and clinically proven solution for the treatment of bone fractures.

 

Bioretec's management estimates that the following factors in particular are the company's key strengths:

• Bioretec has a large and steadily growing addressable market.
• The expected high sales margin of the new RemeOs™ products enables scalability when volumes increase.
• Bioretec has an experienced team executing the commercialization plan.
• Bioretec aims for strong growth with its next-generation RemeOs™ product family. The implants in the new product family are made of a unique biodegradable metal alloy.
  • RemeOs™ products are an excellent and clinically proven effective solution for the treatment of bone fractures.
  • The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing.
  • Bioretec has received FDA market authorization in the U.S. for the RemeOs™ trauma screw in spring 2023.
• The RemeOs™ product family is based on a next generation of strong bioresorbable materials, magnesium alloy and hybrid composite, with better strength characteristics than previous generations of bioresorbable implants, allowing for broader indications.
  • The RemeOs™ product family includes the RemeOs™ trauma screw, RemeOs™ DrillPin, RemeOs™ IM Nail and RemeOs™ spinal cage as well as two new product groups introduced in spring 2023, the RemeOs™ staples and RemeOs™ plates.
• The products in Bioretec’s Activa product portfolio facilitate healing in those orthopedic indications where carrying capacity is not required. Activa products are sold in approximately 40 countries worldwide.